midpage
Slip Opinion
Bankr. D.N.J.
2025
Read the full case

Background

  • Invitae, a medical genetics company, faced severe liquidity stress after multiple acquisitions and large unsecured note maturities in 2024, prompting restructuring efforts and two prepetition exchanges with Deerfield (March and August 2023).
  • The March Exchange converted most 2024 unsecured notes into 2028 secured notes and stock (and added $30M cash); the Committee alleges the transactions advantaged Deerfield and harmed similarly situated unsecured creditors.
  • Invitae filed Chapter 11 in February 2024, entered a Transaction Support Agreement (TSA) with Deerfield at filing, and ran a sale process that produced a Labcorp transaction; Deerfield’s credit-bidding activity increased the sale price.
  • The Official Committee of Unsecured Creditors moved for derivative standing to sue to avoid/recoup the March and August Exchanges and related transfers; the Bankruptcy Court denied standing after evidentiary hearings.
  • The confirmed Chapter 11 Plan (Article VII.C) contained releases of debtors’ claims against Deerfield, certain directors/officers, and other released parties; the Committee appealed both the standing denial and plan confirmation.
  • On limited remand the Bankruptcy Court issued a detailed supplemental opinion crediting an independent director’s investigation and professional testimony; the district court affirmed both the denial of derivative standing and confirmation with releases.

Issues

Issue Plaintiff's Argument Defendant's Argument Held
Whether the Committee should receive derivative standing to sue on estate claims (unjustifiability/cost-benefit) Committee: Debtor unjustifiably refused to pursue colorable fraudulent-transfer and fiduciary-duty claims; litigation would benefit the estate. Debtor/Deerfield: extensive prepetition review, independent investigation, material risks (safe-harbor, exculpation, insolvency disputes), and high cost/delay made declining suit justified. Denied: Bankruptcy Court’s cost-benefit/unjustifiability analysis was reasonable and credited investigator/professional testimony; district court affirmed (abuse-of-discretion review).
Whether the Plan’s non-debtor releases were fair and confirmable Committee: Releases improperly bar pursuit of potentially meritorious estate claims and are overbroad. Debtor/Deerfield: Releases were negotiated consideration; Deerfield and management materially contributed (TSA, credit-bid, cash-collateral, sale process); releases necessary for Plan feasibility and creditor recoveries. Affirmed: Court applied Master Mortgage factors and found identity of interest, substantial contributions, necessity to reorganization, creditor acceptance, and meaningful recoveries supported releases as fair and equitable.

Key Cases Cited

  • Cybergenics Corp. v. Chinery, 330 F.3d 548 (3d Cir.) (derivative standing doctrine for creditors’ committees; trustee/debtor duty to pursue avoidance actions)
  • STN Enters. v. Continental Ins. Co., 779 F.2d 901 (2d Cir.) (test requiring colorable claim and unjustifiable refusal; court performs cost-benefit analysis)
  • In re Adelphia Commc’ns Corp., 544 F.3d 420 (2d Cir.) (bankruptcy-derivative standing discussion and limits on committees’ authority)
  • In re Cohn, 54 F.3d 1108 (3d Cir.) (district court appellate powers over bankruptcy court orders)
  • Meridian Bank v. Alten, 958 F.2d 1226 (3d Cir.) (standards of review for mixed questions of law and fact on bankruptcy appeals)
Read the full case

Case Details

Case Name: Invitae Corporation
Court Name: United States Bankruptcy Court, D. New Jersey
Date Published: Aug 11, 2025
Citations: 2025 WL 2538952; 24-11362
Docket Number: 24-11362
Court Abbreviation: Bankr. D.N.J.
Log In